--- title: "UroGen Pharma (URGN) stock: news and investor profile" url: "https://aibio.space/companies/urogen-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "UroGen Pharma Ltd. (NASDAQ: URGN), United States. The directory classifies it as Biotechnology." --- URGN UroGen Pharma Ltd. NASDAQ · United States # UroGen Pharma (URGN) news Financings · 2026-08-20 ## [UroGen signs option deal with IntraGel and agrees to invest up to $7,000,000](https://aibio.space/news/urogen-signs-option-deal-intragel-agrees-invest-up-7-000-000/) UroGen gets an option on IntraGel's TumoCure for advanced head and neck cancer and agrees to invest up to $7,000,000 in IntraGel's equity. The 8-K gives no clinical data, no option fee and no exercise deadline. ## Latest UroGen Pharma news 1. 2025-02-20 Financings [UroGen Pharma issues 374,843 shares to IconOVir in ICVB-1042 asset purchase](https://aibio.space/news/urogen-pharma-issues-374-843-shares-iconovir-icvb-1042-asset-purchase/) UroGen paid for IconOVir Bio's ICVB-1042 candidate with shares tied to a $4.0 million price, a possible $15.0 million sales milestone and a low single-digit royalty. Entities tied to UroGen's board chair hold IconOVir notes. 2. 2025-02-20 Financings [UroGen buys IconOVir assets for 374,843 shares and a possible $15.0 million payment](https://aibio.space/news/urogen-buys-iconovir-assets-374-843-shares-possible-15-0-million/) The deal covers the product candidate ICVB-1042. A director's affiliates hold IconOVir notes that may entitle them to about 28.3% of the purchase price. ## UroGen Pharma at a glance - **Ticker**: URGN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $109.3 million ### Related companies - [Cogent Biosciences](https://aibio.space/companies/cogent-biosciences/) NASDAQ: COGT - [BridgeBio Pharma](https://aibio.space/companies/bridgebio-pharma/) NASDAQ: BBIO - [Candel Therapeutics](https://aibio.space/companies/candel-therapeutics/) NASDAQ: CADL - [Jasper Therapeutics](https://aibio.space/companies/jasper-therapeutics/) NASDAQ: JSPR - [BioVie](https://aibio.space/companies/biovie/) NASDAQ: BIVI - [SQZ Biotechnologies](https://aibio.space/companies/sqz-biotechnologies/) OTC: SQZB - [EHOUSE GLOBAL INC](https://aibio.space/companies/ehouse-global/) OTC: EHOS - [Edgewise Therapeutics](https://aibio.space/companies/edgewise-therapeutics/) NASDAQ: EWTX ### Also on NASDAQ - [FibroBiologics](https://aibio.space/companies/fibrobiologics/) FBLG - [Roivant Sciences](https://aibio.space/companies/roivant-sciences/) ROIV - [INTELLIGENT BIO SOLUTIONS INC.](https://aibio.space/companies/intelligent-bio-solutions/) INBS - [C4 Therapeutics](https://aibio.space/companies/c4-therapeutics/) CCCC - [GE HealthCare Technologies](https://aibio.space/companies/ge-healthcare-technologies/) GEHC - [ProMIS Neurosciences](https://aibio.space/companies/promis-neurosciences/) PMN ## UroGen Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$67.1 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/) | [$57.1 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/) | | Net income (loss) | [-$153.5 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/) | [-$126.9 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/) | | Cash from operations | [-$162.4 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/) | [-$96.8 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/) | | Cash and equivalents | [$110.7 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926025794/) | [$172.0 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/) | | Short-term investments | [$49.3 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/) | [$110.7 million](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $79.1 million, plus short-term investments of $30.2 million, $109.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about UroGen Pharma What is the ticker symbol of UroGen Pharma? UroGen Pharma Ltd. trades under the ticker URGN on NASDAQ. Where is UroGen Pharma listed? UroGen Pharma Ltd. is listed on NASDAQ. Our directory also records these other listings: GETTEX:UR8; LS:A2DTCV; LSE:0XOD. What is the SEC CIK of UroGen Pharma? The SEC Central Index Key (CIK) for UroGen Pharma Ltd. is 1668243. Its filings are on SEC EDGAR. How many shares does UroGen Pharma have outstanding? 48,880,564 shares as of 2026-07-28, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is UroGen Pharma listed under? Our directory records UroGen Pharma Ltd. under United States. What does UroGen Pharma do? Our directory classifies UroGen Pharma Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of UroGen Pharma? The ISIN recorded for UroGen Pharma Ltd. is IL0011407140. Does aibio.space cover UroGen Pharma? aibio.space lists UroGen Pharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is UroGen Pharma incorporated? SEC records list its state or country of incorporation as L3. Is UroGen Pharma profitable? UroGen Pharma Ltd. reported a net loss of $153.5 million for the fiscal year ended Dec 31, 2025, and used $162.4 million of cash in operations, per its annual report to the SEC. How much does UroGen Pharma spend on research and development? $67.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does UroGen Pharma have? $109.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest UroGen Pharma (URGN) stock news? Our latest story on UroGen Pharma, dated Aug 20, 2026: "UroGen signs option deal with IntraGel and agrees to invest up to $7,000,000". UroGen gets an option on IntraGel's TumoCure for advanced head and neck cancer and agrees to invest up to $7,000,000 in IntraGel's equity. The 8-K gives no clinical data, no option fee and no exercise deadline. [Source](https://aibio.space/news/urogen-signs-option-deal-intragel-agrees-invest-up-7-000-000/). What is UroGen Pharma's latest stock offering or financing news? Our latest financing story, dated Aug 20, 2026: "UroGen signs option deal with IntraGel and agrees to invest up to $7,000,000". UroGen gets an option on IntraGel's TumoCure for advanced head and neck cancer and agrees to invest up to $7,000,000 in IntraGel's equity. The 8-K gives no clinical data, no option fee and no exercise deadline. [Source](https://aibio.space/news/urogen-signs-option-deal-intragel-agrees-invest-up-7-000-000/). How long will UroGen Pharma's cash last? From our story of Feb 20, 2025: That report is nearly a year old at the time of this 8-K. It reported cash and cash equivalents and marketable securities of $141.5 million at December 31, 2023, and it said the company's losses and negative operating cash flows since inception raise substantial doubt about its ability to continue as a going concern. [Source](https://aibio.space/news/urogen-pharma-issues-374-843-shares-iconovir-icvb-1042-asset-purchase/). ## Investor discussion: UroGen Pharma Members talk about UroGen Pharma (URGN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at UroGen Pharma, newest first. Each line links the filing it comes from. 1. 2026-08-20 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1668243/000143774926028590/urgn20260819_8k.htm) 2. 2025-02-20 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02). [Source](https://www.sec.gov/Archives/edgar/data/1668243/000119312525030143/d897858d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:URGN on TradingView](https://www.tradingview.com/symbols/NASDAQ-URGN/). ## SEC filings and registration - **SEC name**: UroGen Pharma Ltd. - **CIK**: 1668243 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: URGN (Nasdaq) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 9 HA'TA'ASIYA ST, RA'ANANA, Israel, 4365007 - **Phone**: 972 9 770 7601 - **Shares outstanding**: 48,880,564 as of 2026-07-28 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1668243/000143774926028590/urgn20260819_8k.htm) filed 2026-08-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1668243/000143774926025794/urgn20260630_10q.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/urgn20260730_8k.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1668243/000143774926021442/urgn20260622_8k.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1668243/000143774926019102/urgn20260601_8k.htm) filed 2026-06-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1668243/000143774926015019/urgn20260331_10q.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/urgn20260504_8k.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1668243/000143774926014237/urgn20260312_def14a.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001668243), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details UroGen Pharma Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker URGN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: UroGen Pharma Ltd. - **Ticker**: URGN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: IL0011407140 - **Other listed symbols**: GETTEX:UR8; LS:A2DTCV; LSE:0XOD - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-URGN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/urogen-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "UroGen Pharma (URGN) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/urogen-pharma/